Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lantheus Holdings is a radiopharmaceutical company specializing in diagnostic and therapeutic nuclear medicine products, with its flagship PYLARIFY (piflufolastat F 18) PET imaging agent for prostate cancer detection driving recent growth. The company operates manufacturing facilities in North Billerica, MA and Montreal, Canada, serving hospitals and imaging centers primarily in the US and Europe. Lantheus has transitioned from a legacy cardiac imaging business (DEFINITY, TechneLite) to a high-growth oncology-focused portfolio, with PYLARIFY representing an estimated 60-65% of revenue as of late 2025.
Lantheus manufactures and distributes radiopharmaceuticals with short half-lives requiring just-in-time production and cold-chain logistics, creating high barriers to entry. PYLARIFY competes in the PSMA PET imaging market against Novartis' Pluvicto/Locametz, with pricing estimated at $2,500-3,500 per dose and gross margins exceeding 70% due to proprietary manufacturing and limited competition. The company benefits from Medicare reimbursement coverage (established 2021) and growing adoption as prostate cancer staging becomes standard of care. Legacy cardiac products provide stable cash flow with 50+ year market presence, though growth is minimal. Operating leverage is moderate-to-high as fixed manufacturing costs are absorbed across growing PYLARIFY volumes.
PYLARIFY quarterly dose volumes and market share vs Novartis in PSMA PET imaging (estimated 40,000-50,000 doses per quarter as of Q4 2025)
Medicare reimbursement rate changes or coverage expansion for PET imaging procedures
Clinical trial readouts and regulatory milestones for therapeutic pipeline candidates (particularly PSMA-targeted therapies)
Manufacturing capacity expansions or supply chain disruptions affecting radioisotope availability (Fluorine-18, Molybdenum-99)
Competitive dynamics with Novartis Pluvicto/Locametz and potential new PSMA imaging entrants
Radioisotope supply chain concentration - dependence on limited global suppliers of Molybdenum-99 (for TechneLite) and Fluorine-18 production capacity creates vulnerability to geopolitical disruptions or reactor shutdowns
Medicare reimbursement policy changes - CMS rate cuts or coverage restrictions for PET imaging could materially impact PYLARIFY economics, though current coverage is stable through 2026
Technological obsolescence - next-generation imaging modalities or alternative prostate cancer biomarkers could disrupt PSMA PET imaging demand over 5-10 year horizon
Novartis market share gains - Pluvicto (therapeutic) bundled with Locametz (diagnostic) creates integrated offering that could pressure PYLARIFY volumes if urologists/oncologists prefer single-vendor solutions
New PSMA imaging entrants - multiple companies developing competing F-18 or Ga-68 labeled PSMA agents, though regulatory approval timelines extend to 2027-2028
Pricing pressure from payer consolidation - as commercial insurers and Medicare negotiate more aggressively, per-dose pricing power may erode from current $2,500-3,500 levels
Moderate debt load - $275M debt against $5B market cap is manageable, but limits financial flexibility for large M&A without equity dilution
R&D execution risk - therapeutic pipeline requires $100M+ annual investment with binary outcomes; clinical trial failures would eliminate growth optionality beyond PYLARIFY
low - Healthcare utilization for cancer diagnostics is largely non-discretionary and driven by disease incidence rather than economic conditions. Prostate cancer screening and staging procedures continue regardless of GDP growth, though hospital capital equipment budgets for PET scanners may be modestly affected during severe recessions. Medicare/insurance reimbursement provides revenue stability.
Moderate sensitivity through two channels: (1) Lantheus carries $275M in debt (0.55 D/E ratio), so rising rates increase interest expense modestly, though operating cash flow of $500M provides ample coverage; (2) As a growth stock trading at 3.3x sales, valuation multiples compress when risk-free rates rise and investors rotate from growth to value. The 10-year Treasury yield affects discount rates applied to future cash flows from pipeline assets.
Minimal - Customers are primarily hospitals and imaging centers with stable payment histories, and Medicare/commercial insurance reimbursement reduces collection risk. The company's 2.67 current ratio and strong free cash flow generation indicate no liquidity concerns.
growth - Investors are attracted to PYLARIFY's 30-40% annual growth trajectory in an expanding prostate cancer diagnostics market, with potential upside from therapeutic pipeline optionality. The stock appeals to healthcare-focused growth funds and biotech specialists willing to accept binary clinical trial risk. Recent 38% three-month return reflects momentum following strong commercial execution, though -10% one-year return indicates volatility around pipeline milestones and competitive concerns.
high - As a mid-cap specialty pharmaceutical with concentrated revenue from a single product (PYLARIFY) and binary pipeline events, the stock exhibits elevated volatility. Beta likely exceeds 1.3-1.5 relative to broader market. Quarterly earnings beats/misses on PYLARIFY volumes can drive 10-15% single-day moves, and clinical trial readouts create event-driven volatility.
